Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.

Chung AW, Crispin M, Pritchard L, Robinson H, Gorny MK, Yu X, Bailey-Kellogg C, Ackerman ME, Scanlan C, Zolla-Pazner S, Alter G.

AIDS. 2014 Nov 13;28(17):2523-30. doi: 10.1097/QAD.0000000000000444.

2.

Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner.

Musich T, Li L, Liu L, Zolla-Pazner S, Robert-Guroff M, Gorny MK.

J Virol. 2017 Mar 29;91(8). pii: e02325-16. doi: 10.1128/JVI.02325-16. Print 2017 Apr 15.

3.

Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.

Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H.

J Immunol. 2010 Dec 1;185(11):6876-82. doi: 10.4049/jimmunol.1002600. Epub 2010 Nov 1.

4.

Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.

Acharya P, Tolbert WD, Gohain N, Wu X, Yu L, Liu T, Huang W, Huang CC, Kwon YD, Louder RK, Luongo TS, McLellan JS, Pancera M, Yang Y, Zhang B, Flinko R, Foulke JS Jr, Sajadi MM, Kamin-Lewis R, Robinson JE, Martin L, Kwong PD, Guan Y, DeVico AL, Lewis GK, Pazgier M.

J Virol. 2014 Nov;88(21):12895-906. doi: 10.1128/JVI.02194-14. Epub 2014 Aug 27.

5.

Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.

Gohain N, Tolbert WD, Acharya P, Yu L, Liu T, Zhao P, Orlandi C, Visciano ML, Kamin-Lewis R, Sajadi MM, Martin L, Robinson JE, Kwong PD, DeVico AL, Ray K, Lewis GK, Pazgier M.

J Virol. 2015 Sep;89(17):8840-54. doi: 10.1128/JVI.01232-15. Epub 2015 Jun 17.

6.

Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.

Hodoniczky J, Zheng YZ, James DC.

Biotechnol Prog. 2005 Nov-Dec;21(6):1644-52.

PMID:
16321047
7.

Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody.

Pace D, Lewis N, Wu T, Gillespie R, Leiske D, Velayudhan J, Rohrbach A, Connell-Crowley L.

Biotechnol Prog. 2016 Sep;32(5):1181-1192. doi: 10.1002/btpr.2300. Epub 2016 Jun 7.

PMID:
27160519
8.

Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.

Dashivets T, Thomann M, Rueger P, Knaupp A, Buchner J, Schlothauer T.

PLoS One. 2015 Dec 11;10(12):e0143520. doi: 10.1371/journal.pone.0143520. eCollection 2015.

9.

Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.

Brown EP, Dowell KG, Boesch AW, Normandin E, Mahan AE, Chu T, Barouch DH, Bailey-Kellogg C, Alter G, Ackerman ME.

J Immunol Methods. 2017 Apr;443:33-44. doi: 10.1016/j.jim.2017.01.010. Epub 2017 Feb 3.

10.

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.

Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR.

Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17.

PMID:
23872058
11.

Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.

Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K.

Mol Immunol. 2014 Mar;58(1):132-8. doi: 10.1016/j.molimm.2013.11.017. Epub 2013 Dec 14.

12.

Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.

Ahmed AA, Keremane SR, Vielmetter J, Bjorkman PJ.

J Struct Biol. 2016 Apr;194(1):78-89. doi: 10.1016/j.jsb.2016.02.001. Epub 2016 Feb 2.

14.

Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.

Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M.

Glycobiology. 2007 Jan;17(1):104-18. Epub 2006 Sep 29. Erratum in: Glycobiology. 2007 Oct;17(10):1030.

PMID:
17012310
15.

Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.

Cheng ZJ, Garvin D, Paguio A, Moravec R, Engel L, Fan F, Surowy T.

J Immunol Methods. 2014 Dec 1;414:69-81. doi: 10.1016/j.jim.2014.07.010. Epub 2014 Jul 31.

PMID:
25086226
16.

Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.

Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X, Robinson JE, Seaman MS, Fouts TR, Gallo RC, DeVico AL, Lewis GK.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E69-78. doi: 10.1073/pnas.1217609110. Epub 2012 Dec 13.

17.

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.

Mimoto F, Igawa T, Kuramochi T, Katada H, Kadono S, Kamikawa T, Shida-Kawazoe M, Hattori K.

MAbs. 2013 Mar-Apr;5(2):229-36. doi: 10.4161/mabs.23452. Epub 2013 Feb 13.

18.

Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.

Kurogochi M, Mori M, Osumi K, Tojino M, Sugawara S, Takashima S, Hirose Y, Tsukimura W, Mizuno M, Amano J, Matsuda A, Tomita M, Takayanagi A, Shoda S, Shirai T.

PLoS One. 2015 Jul 22;10(7):e0132848. doi: 10.1371/journal.pone.0132848. eCollection 2015.

19.

Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.

Thomann M, Reckermann K, Reusch D, Prasser J, Tejada ML.

Mol Immunol. 2016 May;73:69-75. doi: 10.1016/j.molimm.2016.03.002. Epub 2016 Apr 6.

20.

Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.

Liu L.

J Pharm Sci. 2015 Jun;104(6):1866-1884. doi: 10.1002/jps.24444. Epub 2015 Apr 14. Review.

PMID:
25872915

Supplemental Content

Support Center